SCHEMBL4422207

SCHEMBL4422207

Cc1cc(Nc2nccc(-c3ccc(N4C[C@@H](C)O[C@@H](C)C4)nc3)n2)ccc1N1CC2CC1CO2

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
STK17A Q9UEE5 2/20 0.45
MYLK4 Q86YV6 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
ZAP70 P43403 11/20 0.42
PRKD3 O94806 2/20 0.39
PRKCG P05129 2/20 0.39
PRKCB P05771 2/20 0.39
LCK P06239 2/20 0.39
PRKCA P17252 2/20 0.39
PRKCH P24723 2/20 0.39
PRKCI P41743 2/20 0.39
PRKCE Q02156 2/20 0.39
PRKCQ Q04759 2/20 0.39
PRKCZ Q05513 2/20 0.39
PRKCD Q05655 2/20 0.39
PRKD1 Q15139 2/20 0.39
EGFR P00533 1/20 0.39
SYK P43405 1/20 0.39
MAP3K12 Q12852 5/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4426180 1.00 STK17A (0.45) STK17AMYLK4CLK4ZAP70PRKD3
SCHEMBL4422212 1.00 STK17A (0.45) STK17AMYLK4CLK4ZAP70PRKD3
SCHEMBL4426176 1.00 STK17A (0.45) STK17AMYLK4CLK4ZAP70PRKD3
SCHEMBL4286106 0.91 STK17A (0.48) STK17AMYLK4CLK4ZAP70SYK
SCHEMBL4276690 0.91 STK17A (0.48) STK17AMYLK4CLK4ZAP70SYK
SCHEMBL4279074 0.89 ZAP70 (0.54) STK17AMYLK4CLK4ZAP70PRKD3
SCHEMBL4281318 0.89 ZAP70 (0.54) STK17AMYLK4CLK4ZAP70PRKD3
SCHEMBL4279327 0.88 ZAP70 (0.43) ZAP70PRKD3PRKCGPRKCBLCK
SCHEMBL4279324 0.88 ZAP70 (0.43) ZAP70PRKD3PRKCGPRKCBLCK
SCHEMBL4277403 0.88 ZAP70 (0.43) ZAP70PRKD3PRKCGPRKCBLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624229-B2 Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases RIGEL PHARMACEUTICALS, INC. (US) 2017-04-18 US disclosed
EP-2265607-B1 PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES RIGEL PHARMACEUTICALS INC (US) 2016-12-14 EP disclosed
US-20140213585-A1 PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES RIGEL PHARMACEUTICALS, INC. (US) 2014-07-31 US disclosed
US-8309566-B2 Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases RIGEL PHARMACEUTICALS, INC. (US) 2012-11-13 US disclosed
US-20090258864-A1 PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES RIGEL PHARMACEUTICALS, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213585-A1 PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES JAK2, JAK1, JAK3 STK17A 247/4885MYLK4 1575/4885CLK4 1184/4885
US-20090258864-A1 PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES JAK2, JAK1, JAK3 STK17A 229/4885MYLK4 1872/4885CLK4 689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.